Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$136.70 USD
+6.61 (5.08%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $136.72 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Quest Diagnostics (DGX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$143.00 | $155.00 | $125.00 | 9.92% |
Price Target
Based on short-term price targets offered by 14 analysts, the average price target for Quest Diagnostics comes to $143.00. The forecasts range from a low of $125.00 to a high of $155.00. The average price target represents an increase of 9.92% from the last closing price of $130.09.
Analyst Price Targets (14)
Broker Rating
Quest Diagnostics currently has an average brokerage recommendation (ABR) of 2.47 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 2.47 a month ago based on 15 recommendations.
Of the 15 recommendations deriving the current ABR, four are Strong Buy, representing 26.67% of all recommendations. A month ago, Strong Buy represented 26.67%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 11 | 11 | 11 | 11 | 11 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.47 | 2.47 | 2.47 | 2.47 | 2.57 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
3/20/2024 | Truist Securities | David S Macdonald | Hold | Hold |
2/26/2024 | SVB Securities | Michael Cherny | Not Available | Hold |
2/8/2024 | Piper Sandler | David M Westenberg | Hold | Hold |
2/1/2024 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
11/28/2023 | Robert W. Baird & Co. | Eric W Coldwell | Hold | Hold |
11/16/2023 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
10/11/2023 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.47 |
ABR (Last week) | 2.47 |
# of Recs in ABR | 15 |
Average Target Price | $143.00 |
LT Growth Rate | 5.30% |
Industry | Medical - Outpatient and Home Healthcare |
Industry Rank by ABR | 156 of 252 |
Current Quarter EPS Est: | 1.86 |